Mandate

Vinge advises the Swedish state in connection with the recapitalization of SAS

Vinge advises the Swedish state in connection with the recapitalization of SAS. The recapitalization plan, which includes State aid that has been approved by the EU Commission, restores SAS’ equity by SEK 14.25 billion and secures approximately SEK 12 billion of new funding.

The recapitalization plan consists of a directed issue of shares to the Swedish and Danish states, a rights issue of shares to existing shareholders, two directed issues of hybrid notes, of which one is directed to the Swedish and Danish states and one is directed to the Danish state, as well as conversion of existing hybrid notes into shares and of existing bonds into new hybrid notes or shares. The conversion of debt instruments aims at distributing the economic burden of the company’s recapitalization. In aggregate, the Swedish state provides SAS with SEK 5 billion in connection with the recapitalization of the company.

Vinge’s team consisted of Charlotte Levin, Erik Sjöman, Martin Johansson, Amanda Knutsson, Hedvig Josefson and Julia Hirschberg.

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025